DNA vaccine encoding the moonlighting protein Onchocerca volvulus glyceraldehyde-3-phosphate dehydrogenase (Ov-GAPDH) leads to partial protection in a mouse model of human filariasis  by Steisslinger, Vera et al.
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River  blindness,  caused  by the  ﬁlarial  parasite  Onchocerca  volvulus,  is a  major  socio-economic  and  public
health  problem  in Sub-Saharan  Africa.  In January  2015,  The  Onchocerciasis  Vaccine  for  Africa  (TOVA)  Ini-
tiative  has been  launched  with  the  aim  of  providing  new tools  to complement  mass  drug  administration
(MDA)  of ivermectin,  thereby  promoting  elimination  of onchocerciasis  in  Africa.  In this  context  we  here
present  Onchocerca  volvulus  glyceraldehyde-3-phosphate  dehydrogenase  (Ov-GAPDH)  as  a possible  DNA
vaccine candidate.  We  report  that in  a laboratory  model  for ﬁlariasis,  immunization  with  Ov-GAPDH  led
to a  signiﬁcant  reduction  of adult  worm  load  and  microﬁlaraemia  in  BALB/c  mice  after  challenge  infec-
tion  with  the  ﬁlarial  parasite  Litomosoides  sigmodontis.  Mice  were  either  vaccinated  with  Ov-GAPDH.DNA
plasmid  (Ov-pGAPDH.DNA)  alone  or  in  combination  with  recombinantly  expressed  Ov-GAPDH  protein
(Ov-rGAPDH).  During  the  following  challenge  infection  of immunized  and  control  mice with  L.  sigmod-
ontis,  those  formulations  which  included  the  DNA  plasmid,  led to a signiﬁcant  reduction  of  adult  worm
loads  (up to 57%  median  reduction)  and  microﬁlaraemia  (up  to 94%  reduction)  in immunized  animals.  In
a  further  experiment,  immunization  with  a mixture  of  four  overlapping,  synthetic  Ov-GAPDH  peptides
(Ov-GAPDHpept),  with  alum  as adjuvant,  did  not  signiﬁcantly  reduce  worm  loads.  Our  results  indicate
that  DNA  vaccination  with  Ov-GAPDH  has  protective  potential  against  ﬁlarial  challenge  infection  in  the
mouse  model.  This  suggests  a  transfer  of  the  approach  into  the  cattle  Onchocerca  ochengi  model,  where  it  is
possible  to investigate  the  effects  of  this  vaccination  in  the  context  of  a natural  host–parasite  relationship.
©  2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
The parasitic ﬁlarial nematode Onchocerca volvulus, the
ausative agent of human onchocerciasis, affects approximately 37
illion people in the tropics and is still one of the major neglected
iseases in Sub-Saharan Africa [1]. Adult worms, residing in sub-
utaneous nodules, release microﬁlariae that are responsible for
ermal pathology and/or blindness.
Abbreviations: Mf,  microﬁlaria(e); OvE, Onchocerca volvulus somatic extract;
sE,  Litomosoides sigmodontis somatic extract; GAPDH, glyceraldehyde-3-phosphate
ehydrogenase; PBS, phosphate buffered saline; ELISA, enzme-linked immunosor-
ent assay; Ig, immunoglobulin(s); PI, putative immune individual.
∗ Corresponding author at: Bernhard Nocht Institute for Tropical Medicine,
ernhard-Nocht-Strasse 74, 20359 Hamburg, Germany; Tel.: +49 40 42818 470;
ax: +49 40 42818 400.
E-mail address: Erttmann@bni-hamburg.de (K.D. Erttmann).
ttp://dx.doi.org/10.1016/j.vaccine.2015.07.110
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article 
/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Substantial improvements have been achieved over the last
40 years by the implementation of various control programs,
rendered possible mainly through the joined effort of four organi-
zations: the World Health Organization (WHO), the United Nations
Development Program (UNDP), the World Bank and the Food and
Agriculture Organization of the United Nations (FAO). From 1974
through 2002, the Onchocerciasis Control Programme (OCP) in
West Africa focussed on vector control using insecticides. In 1989
ivermectin mass treatment was initiated and extended in 1995
through the African Programme for Onchocerciasis Control (APOC)
[2].
Today however, disease-modeling studies indicate that – even
after 50 years of annual ivermectin treatment – the parasite reser-
voir cannot be eradicated. Turner et al. point out, that the essential
assumption of the cumulative effect of ivermectin treatment might
not be maintainable and irreversible reductions of O. volvulus
microﬁlariae production by 30–35% following each annual round
of ivermectin might be not realistic [3]. Furthermore, as ivermectin
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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with Ov-pGAPDH.DNA plus recombinant Ov-GAPDH protein (Ov-
rGAPDH). The boost injection was  applied 2 weeks after priming.862 V. Steisslinger et al. / V
esistance is increasing, additional measures such as the devel-
pment of alternative drugs and/or a complementary vaccine are
rgently needed [4,5]. In this context, the Onchocerciasis Vaccine
TOVA) – Initiative was started in 2015, with the aim to promote
esearch towards the development of an onchocerciasis vaccine for
frica [6]. Vaccination studies undertaken with irradiated larvae
n the cattle Onchocerca ochengi model of human onchocerciasis
ave provided proof of principle for immunoprophylaxis in a nat-
ral parasite–host relationship under both experimental and ﬁeld
onditions [7,8].
In the present study, we used the DNA plasmid of the mul-
ifunctional protein glyceraldehyde-3-phosphate dehydrogenase
GAPDH) of O. volvulus for immunization against the rodent
laria Litomosoides sigmodontis. As we have previously shown, the
ecombinantly expressed protein has GAPDH enzymatic activity
s well as plasminogen-binding capacity. Histologically, besides
ther locations, labeling was observed in the pseudocoeloma
avity and in a subset of cell nuclei of adult O. volvulus, sug-
esting additional, non-glycolytic functions of the Ov-GAPDH
9].
The protein belongs to the group of today more than 300
roteins expressing multiple functional activities. Many of these
roteins have originally been described as glycolytic enzymes [10].
ultitasking – now designated as moonlighting proteins [11] as
APDH have been described already in 1991 [12] and can act
n manifold ways at the host–parasite interface. With regard to
hat, GAPDH stands out as the “prototype” of a moonlighting pro-
ein, showing intracellular [13] and extracellular functions [10].
onzález-Miguel et al. found GAPDH on the surface and in the
xcretory/secretory (ES) antigens of Diroﬁlaria immitis [14]. Its
lasminogen-binding activity [9] suggests a role in host invasion
nd binding of complement molecules by helminth GAPDH protects
he parasitic nematode Haemonchus contortus from complement
ttack [15]. This leads to the assumption that a GAPDH vaccine
ay  target multiple physiological reactions of the parasite. GAPDH
accines for veterinary use are being generated [16,17] and Schis-
osoma mansoni GAPDH is a strong candidate in the development
f a human vaccine [18,19].
DNA plasmid vaccines have been described to mimic  the effects
f live attenuated vaccines [20] by stimulating both humoral and
ellular immune responses [21]. A trait of DNA vaccines is their abil-
ty to facilitate the development of a Th1-biased or a mixed TH1/Th2
mmune response [20]. As it is known for putatively immune indi-
iduals living in O. volvulus endemic regions [22–24], as well as
or L. sigmodontis infections in the mouse model [25,26] involve-
ent of Th1-associated mechanisms is host protective. Thus it
as our intention to focus our study on the DNA vaccine, which
ay be able to support, even if transiently, the development of
 mixed Th1/Th2 immune response. For veterinary use, DNA vac-
ines have already proven efﬁcacy and have been licensed for
arge animals [27]. With regard to O. volvulus, signiﬁcant protec-
ion has been reported after DNA vaccination against O. volvulus
hitinase in a mouse model [28]. Additionally, compared with con-
entional vaccines, DNA vaccines can be rapidly manufactured at
ower cost, remain more temperature-stable under local conditions
nd are easy to store and transport, likely not requiring a cold chain
20,29].
As the mouse model used in the present study has been
ell established for O. volvulus vaccine development [30], we
nalyzed the effect of Ov-pGAPDH.DNA vaccinations on the
arasitological outcome of the subsequent infection with L. sig-
odontis infective larvae (L3). Furthermore, we investigated the
mmunogenic potential of the vaccine via the detection of GAPDH-
peciﬁc immunoglobulins by ELISA, thus taking advantage of the
igh immunological cross-reactivity between L. sigmodontis and
nchocerca spp. [31]. 33 (2015) 5861–5867
2. Materials and methods
In Fig. 1, we  show the experimental scheme and the workﬂow
of the experiments.
2.1. L. sigmodontis and mice
The experimental infection of BALB/c mice with the rodent
ﬁlaria L. sigmodontis has been established as described by Petit et al.
[32]. L. sigmodontis was  maintained in the tropical cotton rat (Sig-
modon hispidus) and cyclically passaged through the mite vector
Ornithonyssus bacoti [33]. Four- to six-week-old female BALB/c mice
were obtained from Charles River Laboratories (Sulzfeld, Germany)
and kept under pathogen-free conditions in ﬁlter-topped, individ-
ually ventilated micro-isolator cages, receiving sterilized food and
water. Maintenance of BALB/c mice, the L. sigmodontis cycle in cot-
ton rats and the experimental infections were carried out at the
animal facility of the Bernhard Nocht Institute for Tropical Medicine
(BNITM) with permission of the Federal Health Authorities of the
State of Hamburg, Germany.
2.2. Preparation of plasmid DNA
Cloning and puriﬁcation of the Ov-pGAPDH.DNA vaccination
construct and the expression of the recombinant protein was car-
ried out as we had described earlier [9]. In all experiments, control
animals were sham-immunized with the respective carrier sub-
stance used for the vaccine.
2.3. Preparation of antigens
Whole worm extracts were prepared from L. sigmodontis (Ls-
extract/LsE) and O. volvulus (Ov-extract/OvE) adult females as
previously described [34,35].
Synthetic Ov-GAPDH peptides (Ov-GAPDHpept) P1-4 (Eurogen-
tec, Germany) were chosen from areas with lowest homology to
human GAPDH and high homology to S. mansoni-GAPDH peptides
with immunogenic and protective properties [18]. The Ov-GAPDH
peptides P1-4 are each 18 amino acids (aa) long, covering aa 20–37
for Ov-GAPDH-P1, aa 83–100 for Ov-GAPDH-P2, aa 142–159 for
Ov-GAPDH-P3, and aa 256–237 for Ov-GAPDH-P4. Compared to
human GAPDH, Ov-GAPDH peptides P2 and P4 are 50.0% conserved,
peptides P1 and P3 are 55.6% conserved.
2.4. Ov-pGAPDH.DNA vaccination experiments
In four Ov-pGAPDH.DNA identical vaccination experiments, a
total number of 25 mice (3 experiments with n = 6, in one exper-
iment the immunized group held n = 7 animals) received a prime
injection and booster injection 2 weeks later, with a total dose of
200 g Ov-pGAPDH.DNA (100 g at each time-point, 50 g/leg i.m.
tibial). The total number of sham-immunized mice in the control
groups (n = 6 each) amounted to 24 animals. Infections with L. sig-
modontis were performed 2 weeks after the boost, by s.c. injection
of 40 L3 into the neck, as described by Petit et al. [32]. Experiments
were terminated at day 70 post infection (D70) p.i.
2.5. Vaccination with Ov-pGAPDH.DNA plus recombinant
Ov-GAPDH protein
In two  experiments, a total number of 12 mice (n = 6 in
two vaccinated groups of the two  experiments) were vaccinatedOn each point in time, both 100 g Ov-pGAPDH.DNA (50 g/leg
i.m. tibial) and 12 g Ov-rGAPDH (s.c. inguinal, 6 g protein on
V. Steisslinger et al. / Vaccine 33 (2015) 5861–5867 5863
Fig. 1. Experimental scheme. This ﬁgure summarizes the principle of cross-immunization with O. volvulus GAPDH in our mouse model and depicts workﬂow and time line of
the  analyses discussed in this article. Vaccine I: Ov-pGAPDH.DNA. Four identical experiments were carried out (n = 6, the control group in one experiment had n = 7 animals)
in  total 25 animals. Two doses (prime and boost) of 100 g DNA (50 g/leg, i.m. tibial) were applied in bi-weekly intervals. Vaccine II: Ov-pGAPDH.DNA + rGAPDH. Two
identical experiments were carried out (n = 6 in the vaccinated and the control group). Two doses (prime and boost); at both time points 100 g Ov-pGAPDH.DNA (50 g/leg
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h.m.  tibial) and 12 g Ov-rGAPDH (s.c. inguinal, 6 g protein on each side) were app
nd  the control group), two doses (prime and boost) of the Ov-GAPDH peptide coc
egend  of the graphical abstract for references of source of the pictures included in 
ach side) were applied. Twelve sham-immunized mice (two
xperiments → two groups with n = 6 animals) served as controls.
hallenge infections and termination of the experiments were per-
ormed as described above.
.6. Vaccination with Ov-GAPDHpept in alum
In two experiments, a total of 12 mice were vaccinated as
escribed in Sections 2.4 and 2.5 with a cocktail of the four
v-GAPDH peptides in alum. Injections were carried out subcu-
aneously in the neck with a total dose of 2 g peptide cocktail per
nimal (1 g per injection), n = 12 in the control groups. Challenge
nfections and termination of the experiments were performed as
escribed above.
.7. Blood samples
Bleeding of mice was performed by tail vein incision. Time-
oints of bleeding were prior to the ﬁrst immunisation and in
-week intervals pre- and post-challenge in all experiments.
.8. Analysis of worm load
The majority of L. sigmodontis worms reside in the thoracic cav-
ty of the host [32]. For parasitological analysis, mice were sacriﬁced
t day 70 (D70) post infection and adult worms, granulomas and
icroﬁlariae (Mf) were removed from the thoracic cavity. Parasites
ere counted as described by Le Goff et al. [36]. Microﬁlaraemia
as determined at D64 by counting the total number of Mf  in 50 l
eparinized blood after staining with Hinkelmann’s solution.accine III: Ov-GAPDH peptides. Two identical experiments (n = 6 in the vaccinated
n alum (1 mg per injection) were applied s.c. in the neck. Please refer to the ﬁgure
aphic.
2.9. Detection of antibodies by ELISA
For the detection of immunoglobulin (Ig) in mouse plasma,
whole worm extracts (OvE and LsE  as described in Section 2.3)
and the Ov-GAPDH peptides P1-4 were used as antigens. The worm
extracts were adjusted to a ﬁnal concentration of 4 g/ml in car-
bonate buffer pH 9.6; peptides were used at a concentration of
2 g/ml. The assay was  mainly carried out as described elsewhere
[37]. Brieﬂy, 96-well microtiter plates were coated overnight at
4 ◦C with 50 l antigen solution/well. After blocking with 200 l
5% BSA/PBS (w/v) per well for 3 h, appropriate dilutions of control
and test samples (both in 1% BSA/PBS) were applied in duplicates
(50 l/well) and incubated for 2 h at room temperature or overnight
at 4 ◦C. Bound antibody (Ab) was  detected using horseradish perox-
idase (HRP)-labeled monoclonal anti-mouse secondary antibodies
(Zymed/Invitrogen and Dianova, Germany) and developed using
3,3′,5,5′-tetramethylbenzidine (Roth, Karlsruhe), optical density
was measured at 450 nm. For analysis, relative ELISA units were
calculated by subtraction of the negative control (sample buffer)
from the mean OD450 of each sample duplicate on each ELISA plate.
2.10. Statistical analysis
Statistical analyses were performed using GraphPad Prism ver-
sion 4.0c for Macintosh.
Comparison of groups was performed using the Mann–Whitney
U test for non-parametrical data. P-values below 0.05 were consid-
ered signiﬁcant. After statistical veriﬁcation (Kruskal–Wallis test
and Dunn’s multiple comparison test), parasitological data were
pooled for further analysis.
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Fig. 2. (A) Reduction of the number of adult L. sigmodontis in Ov-GAPDH-immunized
mice. Mice were immunized with Ov-pGAPDH.DNA alone (n = 25), plasmid plus
Ov-rGAPDH (n = 12) or the mixture of four synthetically produced Ov-GAPDH pep-
tides in alum (n = 12), respectively. The adult worm count was determined at D70
post infection and the data presented as box and whiskers graphs with quar-
tiles and whiskers. The overlay with the respective scatter graph demonstrates
the  individual values. Statistical analysis of the difference of the medians was
carried out by Mann–Whitney U test. Worm burdens in mice vaccinated with
Ov-pGAPDH.DNA were reduced by 33.25% (P = 0.032), combined vaccination with
Ov-pGAPDH.DNA + rOv-GAPDH yielded a 57.5% reduction (P = 0.002) and the reduc-
tion  seen in the group immunized with Ov-GAPDH peptides amounted to 27% but
was  not signiﬁcant (P = 0.37). (B) Strong reduction of microﬁlariae in Ov-GAPDH-
immunized mice. Microﬁlariae of infected mice were detected in peripheral blood
taken at D64 post infection. The ﬁgure shows Mf  loads of the individual animals
within the respective groups (dot plot within the box and whiskers plot) with n = 13
for  the immunized and n = 12 for the control group. Medians are indicated as hori-
zontal bars in the respective boxes, statistical comparison of the medians was  carried
out by Mann–Whitney U test. The 90.5% reduction we observed after DNApl vaccina-
tion was  signiﬁcant with P = 0.0009. After combined DNA + Ov-rGAPDH vaccination,864 V. Steisslinger et al. / V
. Results
.1. Vaccination of BALB/c mice with O. volvulus-pGAPDH.DNA
onveys pronounced partial protection
.1.1. Reduction of adult L. sigmodontis
BALB/c mice were immunized either (i) with Ov-pGAPDH.DNA
n = 12 subjects) or (ii) with a combination of Ov-pGAPDH.DNA plus
v-rGAPDH protein in alum (n = 12). As a third vaccine formulation
iii), a mix  of four helminth-speciﬁc non-conserved Ov-GAPDH pep-
ides in alum (n = 12) was included. A signiﬁcant reduction in the
dult worm load was observed in vaccinated vs. non-vaccinated
nimals 70 days after infection with L. sigmodontis. The worm
oad was reduced by 33.25% (P < 0.05) after immunization with
v-pGAPDH.DNA alone and by 57.5% (P < 0.01) after vaccination
ith Ov-pGAPDH.DNA plus Ov-rGAPDH protein. In contrast, immu-
ization with the four Ov-GAPDH peptides – representing 21% of
he Ov-GAPDH amino acids – resulted in a non-signiﬁcant 27%
eduction of the worm count (Fig. 2A). In all vaccinated groups,
e observed a more pronounced decrease in numbers of female
han male worms (data not shown). Further, female worms were
horter in DNA-vaccinated (−27%, P < 0.02) and in Ov-GAPDHpept-
accinated mice (−39.7%, P < 0.01) compared to the female worms
n the control groups.
.1.2. Strong reduction of microﬁlariae
High protection rates were observed with regard to the microﬁ-
arial load of the infected mice determined 64 days after infection.
n comparison to the control groups, microﬁlaraemia was reduced
y 90.5% (P < 0.001) after immunization with the Ov-pGAPDH.DNA
accine and by 94.5% (P < 0.002) after immunization with the
ombined vaccine (Fig. 2B). In contrast, the immunization with
v-GAPDHpept resulted in only 61.5% reduction of microﬁlariae
Fig. 2B).
.2. Vaccination with Ov-pGAPDH.DNA induced pre-challenge Ig
esponses directed against O. volvulus worm extract and
v-GAPDH peptides
On day 15 after the booster injection of Ov-pGAPDH.DNA,
e found increased Ov-extract- and Ov-GAPDHpept-speciﬁc IgM
evels (Fig. 3A) and low but detectable worm extract- and Ov-
APDHpept-speciﬁc IgG reactivity (Fig. 3B). No difference in IgG1
evels was observed between vaccinated and control mice at this
ime point (Fig. 3B), while we found differential IgG2a- (Fig. 3B)
nd IgM-activity (Fig. 3A), characterized by a signiﬁcantly enhanced
nti-Ov-GAPDHpept activity in immunized mice (P = 0.041 for IgG2a
nd P = 0.008 for IgM).
The development of the vaccine-induced Ig response after
NA + protein immunization was monitored in a small parallel
xperiment. Here, a strong and predominant IgG1 response was
bserved while no IgG2 was detectable (data not shown), indicat-
ng that, as one might expect, the protein part of the formulation
nhanced the Th2 arm of the response [20].
.3. Signiﬁcant effect of DNA vaccination on the antibody
esponse during the ﬁrst third of the challenge infection with L.
igmodontis
Signiﬁcantly elevated anti-Ov-GAPDHpept-reactive IgM and
gG1 antibody levels were observed in the plasma of only DNA vac-
ine immunized mice at day 25 post infection with L. sigmodontis
Fig. 4). The highest relative increase was observed for IgM- and IgG-
eactivity with the four Ov-GAPDH peptides. The increase of anti-
ody response was less pronounced when directed against antigens
n the extract from O. volvulus and L. sigmodontis – comprising94.5% reduction of Mf  were found in the immunized group (P = 0.0015). Mf numbers
in Ov-GAPDH peptide immunized mice were reduced by 61.5%, but this was not
signiﬁcant (P = 0.09).
Ov-GAPDH and Ls-GAPDH. Anti worm extract IgM- but not IgG1-
reactivity was  signiﬁcantly elevated in DNA vaccinated mice
compared to the controls (Fig. 4). After challenge infection, no IgG2
reactivity was detectable over the course of the infection (data not
shown).
By day 35 post challenge infection, the previously (day 25, Fig. 4)
differential worm-extract speciﬁc antibody responses in the immu-
nized and the control groups had equaled (data not shown). Only
the Ov-GAPDH peptide-speciﬁc IgM response was still signiﬁcantly
higher in the immunized group (P = 0.04, data not shown). We  also
investigated antibody levels at late timepoints, especially after the
onset of patency (after day 55 until termination of the experiments),
but found no signiﬁcant differences between the groups.4. Discussion
Despite the great progress made in controlling onchocerciasis
due to the mass drug administration (MDA) programmes, it is clear
V. Steisslinger et al. / Vaccine 33 (2015) 5861–5867 5865
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Fig. 3. DNA vaccination induced anti-Ov-GAPDH peptide and anti-Ov extract
immunoglobulin activity prior to the challenge infection with L. sigmodontis. The
Ig  activity directed against worm extract and the Ov-GAPDH peptides was  deter-
mined by ELISA (O.D.450). Measurements were individually carried out for each
animal in the respective experimental groups (n = 6/6). The data presented here
are representative of the four DNA-vaccination experiments in this study. Statistical
analysis of ELISA data was  carried out by Mann–Whitney U test. (A) 15 days after Ov-
pGAPDH.DNA vaccination and prior to the challenge infection with L. sigmodontis,
Ov-GAPDH peptide-speciﬁc IgM levels were signiﬁcantly higher in the immunized
group than in the control group (P = 0.008). Levels of OvE-speciﬁc IgM were also ele-
vated but the increase was not signiﬁcant (P = 0.065). (B) The levels of IgG1 directed
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Fig. 4. Signiﬁcantly increased anti-Ov-GAPDH IgM and IgG1 in peripheral blood
at  D25 post infection with L. sigmodontis after preceding Ov-pGAPDH.DNA immu-
nization. (A) At day 25 p.i., serum IgM levels directed against all three antigens
were signiﬁcantly higher in the Ov-pGAPDH.DNA immunized group (P = 0.027 for
anti-Ov-extract activity, P = 0.015 for anti-Ls extract activity and P = 0.008 for anti-ion, whereas IgG2a reactivity, though remaining on a very low level, showed a clear
ncrease in the immunized group (P = 0.041 for peptide-reactive IgG2a and P = 0.065
or  Ov extract-speciﬁc IgG2a).
hat further tools, such as new drugs or a MDA  complementary
accine, have to be implemented to reach the ﬁnal goal, the elimina-
ion of onchocerciasis. Vaccination remains the most cost-effective
eans of long-term disease control and prevention.
We chose Ov-GAPDH as a vaccine candidate, since it was rec-
gnized by sera of putatively immune individuals (PI) who live
n highly endemic areas for a long period of time without show-
ng any signs of disease or microﬁlariae in their skin [38]. These
I sera recognize relatively few but often highly multifunctional
ntigens like GAPDH and aldolase [39], the latter belongs to the
ntigens already tested in the bovine model of onchocerciasis [40].
sing PI sera, Ov-fructose-1,6-bisphosphate aldolase as well as
v-enolase and Ov-GAPDH were identiﬁed as targets of protec-
ive immune responses in humans ([9,39,41]; Erttmann, Personal
ommunication). On the one hand, these three proteins are mem-
ers of the glycolytic pathway, with catalytic activity shown for
he recombinant Ov-GAPDH [9], on the other hand, all three
olecules are secreted and belong to the special group of the
o called moonlighting proteins [10,13]. They are multifunctional
nd exhibit various intracellular and extracellular functional activ-
ties ([42,43,44]; Brattig, Personal communication). Usually, these
roteins are discussed as targets of the host immune response
n the context of their vital function in energy production of theOv-GAPDH peptide activity, respectively). (B) Signiﬁcance of increased IgG1 levels
at  day 25 p.i. was  reached for anti-Ov-GAPDH peptide activity (P = 0.0022), not for
activity directed against the worm extracts.
parasite via their functions in the glycolytic pathway. This
approach, however, neglects the plethora of additional functional
activities of these proteins. It is conceivable that other functions
beyond the well known intracellular metabolic activities of these
proteins are exposed to the host immune response and thus
involved in immune modulation [10,45–47]. Multiple extracellular
functions can be targeted by host immune responses, making these
proteins valuable vaccine candidates. This is particularly intriguing,
since it seems that these moonlighting proteins are preferentially
recognized by PI sera, regardless of their geographical origin [9,39].
In the case of Ov-GAPDH and Ov-enolase, PI sera were obtained
from a region in Liberia/West Africa, whereas for Ov-aldolase, the
sera originated from a region in Ecuador/South America [39].
Here we report that vaccination against Ov-GAPDH provided
protective efﬁcacy against the infection of mice with the ﬁlaria
L. sigmodontis, a model for human ﬁlariasis. The vaccine formula-
tions including the Ov-pGAPDH.DNA led to signiﬁcant reduction
of adult worm load (up to 57% reduction) and microﬁlaraemia
(up to 95% reduction) in the immunized animals. The protective
effects observed in our study lie in the range of the reduc-
tion rates (68% reduction of adult worms and 85% reduction
of Mf)  achieved in a vaccination experiment by Babayan et al.
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48], whereby the complex DNA vaccine was also evaluated in a
ALB/c/L. sigmodontis-setup that was similar to our experimental
esign. In contrast, using a different model, the DNA immunization
f BALB/c mice with Ov-chitinase reduced the survival of implanted
. volvulus L3 by 53% [28], similar to the result of vaccination
ith the recombinant fructose-1,6-bisphosphate aldolase, where a
eduction of O. volvulus L3 by 50% was reported [39]. In our model it
emains unclear whether the infective 3rd and 4th stage larvae are
argets of the protective mechanisms that are initiated by the vac-
ination. We assume, however, that the reduced Mf  loads, which
e observed in DNA-vaccinated mice, might originate from pro-
ective immune responses directed against Mf,  as low Mf  levels
lso occurred in mice with substantial numbers of adult worms.
dditionally, Mf  reduction might be a consequence of a more pro-
ounced reduction of female than male worm numbers, especially,
s female worms were signiﬁcantly shorter in the immunized mice,
uggesting a decreased fecundity leading to a lower Mf  load.
Our analysis of the vaccine-induced humoral response con-
rmed that the encoded Ov-GAPDH was expressed in vivo. Ig
ubclass analysis served as an indicator of Th-bias and the induc-
ion of antigen-speciﬁc IgG2a corroborated the assumption that
v-pGAPDH.DNA vaccination was able to activate a pre challenge
h1 response. Investigation of the post challenge humoral immune
esponse showed that the vaccine-induced IgM-response was  sub-
equently strong enough to prevail within the mixed antibody
esponse to worm extract (see Fig. 3A and 4A). Signiﬁcant antibody
esponses directed against the four Ov-GAPDH peptides conﬁrmed
hat the vaccination was able to raise antibodies against distinct
utatively protective sections of the Ov-GAPDH molecule (see Sec-
ion 2.3 and ref. [18]). This was also observed at day 25 after
hallenge, even more signiﬁcant for the peptides than for both
orm extracts. For IgG1, signiﬁcance was only reached by the
esponse to the peptides.
The increased Ov-GAPDH-speciﬁc IgG and IgM antibodies prior
o and early in the infection (pre infection/Fig. 3 and day 25/Fig. 4)
ay  be operative in antibody-mediated cellular immune responses
gainst incoming and/or developing larvae [34,49]. For the ﬁlaria
rugia pahangi, Rajan et al. described the direct involvement of
elminth-speciﬁc IgM in macrophage-mediated killing of helminth
arvae [50]. To what extent, similar to Rajans ﬁndings, Ov-GAPDH-
peciﬁc and worm antigen-reactive IgM plays a role in protective
mmunity against ﬁlarial infection in this model has to be further
nvestigated.
In conclusion, Ov-GAPDH is one of several moonlighting pro-
eins of O. volvulus that have been identiﬁed as vaccine candidates
y PI sera, raising the question, if multifunctional proteins play
 key role in immune modulation and protection of the human
ost. Taking into account that GAPDH of other species has been
epeatedly reported as a vaccine candidate against protozoan and
ulticellular pathogens, the results presented in this study qual-
fy onchocercal GAPDH to be included into the group of selected
accine candidates. We  previously tested the compatibility and
ntibody response of Ov-GAPDH in cattle [9], while in the present
tudy we showed the protective potential in the mouse model. The
igniﬁcant protection warrants further vaccination studies in the O.
chengi/cattle model, which represents the natural host–parasite
elationship.
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